At the forefront of scientific discoveries
Founded as Morwell Diagnostics GmbH in Zurich, Switzerland, provider of clinical diagnostic products.
Establishment of manufacturing facilities for clinical products. Representation and distribution in over 75 countries.
Establishment of MD Doctors Direct GmbH for the sale of point of care products into the clinic.
Formal distinction and formation of MD Biosciences for the manufacturing and sale of monoclonal research products and assays. Establishment of monoclonal production facility in Scotland for the production of ArthritoMab®
Establishment of contract research operations focused on joint inflammation.
Expansion of contract research facilities with the establishment of in vivo facilities focused on all inflammatory diseases. Establishment of US based biomarker and assay development laboratories.
Establishment of new laboratory focused on neurodegenerative diseases and pain.
Release of novel porcine translational models.
Release of Senerga ® Phenotypic Screening Platform and formation of the first screening program with Jannsen Research.
Expansion of US based in vivo operations to provide onco-immunology and metabolic disease focus.
Establishment of CLIA accredited clinical analysis laboratory in the US.
Separation of histology and immunohistochemistry laboratory operations as a business unit in conjunction with diagnostic operations.
Expansion of investment and risk-sharing program for the development of compounds of interest.
Research and development for MD 354 (chronic pain), MD 22 (inflammation/pain), and MD401B (canine osteocarcinoma vaccine), panel of biomarkers for gastrointestinal cancer diagnostics.
Release of collaborative investment program to co-invest in promising early stage drug development.